Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression.

[1]  M. Manos,et al.  Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? , 2005, Journal of the National Cancer Institute.

[2]  Yueh-Hsia Chiu,et al.  Mammographic tumor features can predict long‐term outcomes reliably in women with 1–14‐mm invasive breast carcinoma , 2004, Cancer.

[3]  Barbara L. Smith,et al.  The age at which women begin mammographic screening , 2004, Cancer.

[4]  I. Ellis,et al.  Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma , 2004, British Journal of Cancer.

[5]  C. Osborne,et al.  HER-2 Amplification, HER-1 Expression, and Tamoxifen Response in Estrogen Receptor-Positive Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[6]  J. Coebergh,et al.  Breast carcinoma diagnosis, treatment, and prognosis before and after the introduction of mass mammographic screening , 2004, Cancer.

[7]  Kornelia Polyak,et al.  Ductal Carcinoma in Situ of the Breast , 2004, Strahlentherapie und Onkologie.

[8]  M. Echenique,et al.  Mammographic features and correlation with biopsy findings using 11-gauge stereotactic vacuum-assisted breast biopsy (SVABB). , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[10]  Joseph Geradts,et al.  Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. , 2003, AJR. American journal of roentgenology.

[11]  I. Bièche,et al.  Prognostic value of ERBB family mRNA expression in breast carcinomas , 2003, International journal of cancer.

[12]  M. Piccart,et al.  Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Karla Kerlikowske,et al.  Evaluation of Abnormal Mammography Results and Palpable Breast Abnormalities , 2003, Annals of Internal Medicine.

[14]  J. R. Reeves,et al.  Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.

[15]  L. Tabár,et al.  Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening , 2003, The Lancet.

[16]  B. Angus,et al.  Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 , 2003, Journal of clinical pathology.

[17]  Panagiota Ravazoula,et al.  Non‐palpable breast carcinomas: Correlation of mammographically detected malignant‐appearing microcalcifications and molecular prognostic factors , 2002, International journal of cancer.

[18]  K. Kerlikowske,et al.  Detection of ductal carcinoma in situ in women undergoing screening mammography. , 2002, Journal of the National Cancer Institute.

[19]  O. Miettinen,et al.  Mammographic screening: no reliable supporting evidence? , 2002, The Lancet.

[20]  Vassilis G Gorgoulis,et al.  Transcription factors and neoplasia: vistas in novel drug design. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Nesland,et al.  EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.

[22]  Yosef Yarden,et al.  Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.

[23]  D. Barnes,et al.  Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.

[24]  S. Hellman,et al.  Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[26]  F. Akiyama,et al.  What is the predictor for invasion in non-palpable breast cancer with microcalcifications? , 2004, Breast cancer.

[27]  Mark A Helvie,et al.  Invasive cancers detected after breast cancer screening yielded a negative result: relationship of mammographic density to tumor prognostic factors. , 2004, Radiology.

[28]  B. Mesurolle,et al.  Clustering of breast microcalcifications on digital mammography: which parameters? , 2002, Clinical radiology.

[29]  L. Melton,et al.  HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Christophe Schild.  Notions générales sur le réticulosarcome des ganglions lymphatiques et des formations lymphoïdes , 1949 .